The role and clinical significance of myeloperoxidase (MPO) and TNF-α in prognostic evaluation of T-COPD

作者：Erlie Jiang, Yingya Fu, Yalin Wang, Ying Li, Wen Li · 发表于：BMC Pulmonary Medicine · 年份：2025 · DOI：10.1186/s12890-025-03655-4 · 被引用次数：9 · 研究领域：Chronic Obstructive Pulmonary Disease (COPD) Research、Neutrophil, Myeloperoxidase and Oxidative Mechanisms、Inflammation biomarkers and pathways

PURPOSE: Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder that requires effective biomarkers for assessing disease activity and severity. This study aimed to compare clinical characteristics, inflammatory biomarker levels, and pulmonary function between stable COPD (S-COPD) and treated COPD (T-COPD) patients, with a focus on the prognostic value of inflammatory markers such as TNF-α, MPO, and IL-6. METHODS: A total of 81 patients were enrolled in the study, including 39 with stable COPD (S-COPD) and 42 with treated COPD (T-COPD). Clinical characteristics, lung function (measured by FEV1%), and inflammatory biomarkers (IL-6, MMP-9, SAA, MPO, TNF-α, and others) were assessed. Inflammatory biomarkers were compared between the two groups, and their associations with pulmonary function were examined using correlation and regression analyses. Prognostic value was assessed using ROC curve analysis. RESULTS: The T-COPD group exhibited significantly more severe disease, with higher rates of exacerbations, worse quality of life (CAT and mMRC scores), and reduced lung function (FEV1%, 6-minute walk distance). Inflammatory biomarker analysis revealed no significant differences for IL-6, MMP-9, SAA, RDW, LCN2, PLR, and NLR, but TNF-α and MPO were significantly higher in T-COPD patients (P = 0.015 and P = 0.012, respectively). Among these biomarkers, MPO and TNF-α showed strong negative correlations with FEV1% in T-COPD patients (r = -0.521 and r = -0.459...